Profile Response Detail

Molecular Profile BRCA2 mutant
Therapy Olaparib
Indication/Tumor Type Her2-receptor negative breast cancer
Response Type sensitive
Create By tyin
Update By spatt


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRCA2 mutant Her2-receptor negative breast cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a germline BRCA mutation (PMID: 28578601; NCT02000622). 28578601
PubMed Id Reference Title Details
(28578601) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. Full reference...